Inactive Instrument

Cyteir Therapeutics, Inc.

CYTT

US23284P1030

Biotechnology & Medical Research

Cyteir Therapeutics, Inc. Announces Resignation of Adam Veness from His Position as General Counsel and Secretary, to Be Effective as of the Company’S Annual Meeting of Stockholders on June 14, 2023

June 02, 2023 at 09:18 pm

Cyteir Therapeutics, Inc. announced resignation of Adam Veness from his position as General Counsel and Secretary, to be effective as of the Company's Annual Meeting of Stockholders on June 14, 2023.

Latest news about Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions	03-20	CI
Cyteir Therapeutics, Inc.(NasdaqGS:CYT) dropped from S&P TMI Index	03-19	CI
Cyteir Therapeutics, Inc.(OTCPK:CYTT) dropped from NASDAQ Composite Index	03-14	CI
Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors	12-07	CI
Cyteir Therapeutics, Inc. Announces Board Changes	12-05	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Cyteir Therapeutics' Ovarian Cancer Combination Treatment Candidate Shows 91% Overall Disease Control in Phase 1 Study	12/10/23	MT
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer	12/10/23	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Top Midday Gainers	30/06/23	MT
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30/06/23	CI
Cyteir Therapeutics to Discontinue CYT-0851 Development, Plans Dissolution, Liquidation of Assets; Shares Rise Pre-Bell	30/06/23	MT
Cyteir Therapeutics' Board Recommends Liquidation, Dissolution of Assets	30/06/23	MT
Cyteir Therapeutics, Inc. Presents Results from A Phase 1 Study with CYT-0851	03/06/23	CI
Cyteir Therapeutics, Inc. Announces Resignation of Adam Veness from His Position as General Counsel and Secretary, to Be Effective as of the Company’S Annual Meeting of Stockholders on June 14, 2023	02/06/23	CI
Cyteir Therapeutics, Inc. Announces Resignation of Susan Molineaux from the Board of Directors	31/05/23	CI
Athira Pharma Names Andrew Gengos CFO	22/05/23	MT
Cyteir Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Cyteir Therapeutics Appoints David Gaiero Finance Chief	06/02/23	MT
Cyteir Therapeutics, Inc. Announces the Promotion of David Gaiero to Chief Financial Officer	06/02/23	CI
Morgan Stanley Downgrades Cyteir Therapeutics to Underweight From Equal Weight, Adjusts Price Target to $2 From $4	03/02/23	MT
BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $4	30/01/23	MT
Wedbush Lowers Cyteir Therapeutics' Price Target to $3 From $8, Notes 'Disappointing' Monotherapy Results; Keeps Outperform Rating	23/01/23	MT
JPMorgan Downgrades Cyteir Therapeutics to Neutral From Overweight	20/01/23	MT
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development	19/01/23	CI

Chart Cyteir Therapeutics, Inc.

Duration

Period

More charts

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.

Sector

Biotechnology & Medical Research

Calendar

03/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.03%	48.16B
IQVIA HOLDINGS INC.	-0.10%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+9.06%	12.92B
MEDPACE HOLDINGS, INC.	+30.01%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B

Other Biotechnology & Medical Research